Hundreds of billion yuan of prescriptions are going out of the market. Let's see how these five companies are arranged?

[pharmaceutical network industry trends] in the context of two ticket system, "4 + 7" volume procurement, DRGs, and key monitoring of auxiliary drugs.. The sales of prescription drug hospitals have been greatly impacted, and the market outside the hospital has ushered in more opportunities Most people in the industry believe that in the future, China's out of hospital market for prescription drugs has broad prospects According to the data, the scale of prescription outflow will reach 160 billion yuan in 2018, and the total amount of prescription drugs transferred from hospital to hospital is expected to reach nearly trillion yuan by 2020 It is understood that at present, traditional pharmaceutical enterprises such as Sinopharm, China Resources, Shangyao, Huadong pharmaceutical, Jiuzhoutong, ordinary people, Yixintang, dashanlin, Changbu, Zhengda Tianqing have entered the market one after another In addition, a number of innovative enterprises are rising rapidly The author analyzes the situation of five enterprises, which are only for the reference of the industry The main business of Sinopharm is pharmaceutical wholesale and retail For many years, it ranks first in the business income of domestic retail enterprises The number of Direct stores and total stores rank first in China, and the number of retail pharmacies is also increasing In terms of the outflow of prescriptions, the enterprise has established DTP pharmacy, hospital pharmacy, hospital side pharmacy, "5+X" pharmacy and other forms of pharmacy In the pharmaceutical retail business sector, Sinopharm achieved revenue of 14.804 billion yuan in 2018, up 19.46% year on year It is reported that by the end of 2018, the total number of retail pharmacies controlled by the state has reached 5183, an increase of 740 compared with 2017, and the retail network covers 30 provinces, municipalities and autonomous regions, more than 229 cities Huarun medicine Huarun medicine is a wholly-owned large pharmaceutical circulation enterprise of Huarun medicine group In 2018, Cr Pharma launched an extended M & a strategy of "building a platform at the provincial level and laying out a network at the prefecture and city level" Today, the distribution network of Cr Pharma has covered 28 provinces, municipalities and autonomous regions, including 6581 secondary and tertiary hospitals, 51500 primary medical institutions and 26900 retail pharmacies Among them, in the retail business sector, China Resources rose 28.5% year-on-year in 2018, achieving an annual revenue of about 4.667 billion yuan At present, China Resources has 853 retail pharmacies and actively develops innovative business models such as DTP and chronic disease management There are 140 DTP pharmacies in China Resources, covering 66 cities It is reported that China Resources pharmaceutical business group plans to achieve a retail business scale of more than 10 billion by 2020, and strive to enter the top three domestic pharmaceutical retail companies Specifically, the core business will be to develop "professional drugstores" and "community chain drugstores" Shanghai Pharmaceutical is the core enterprise of large health industry under the controlling shareholder Shangshi group, whose main business covers pharmaceutical industry, distribution and retail In the context of the new era of pharmaceutical retail, Shanghai Pharmaceutical achieved sales revenue of RMB 3.134 billion in the first half of 2018, up 15.45% year on year In addition, data shows that in 2018, Shanghai Pharmaceutical retail sector accounted for 4.54% By the end of the report period in the first half of 2018, there were 1981 chain retail pharmacies under Shanghai pharmaceutical, including 1324 Direct stores In addition, Shanghai Pharmaceutical has 50 hospital side pharmacies and 77 DTP pharmacies At the same time, SHP actively participated in the Shanghai community comprehensive reform prescription extension project and assisted in hierarchical diagnosis and treatment At present, it has covered 230 community hospitals and health service centers in Shanghai, with a market share of nearly 70% In the first half of 2018, it has obtained more than 410000 prescriptions, with the same increase of 115.4% In recent years, Huadong pharmaceutical has also actively expanded the out of hospital market In 2018, the annual business growth of private hospitals and community hospitals was more than 25%, and the out of hospital market coverage increased At the same time, the company also carried out in-depth promotion of the retail market, built a cooperative store between DTP pharmacy and hospital, set up a full-time E-commerce Team affiliated to the hospital pharmacy sales team, and carried out differentiated marketing In 2018, 1200 new customers were added, covering more than 80% of the province's chain drugstores Jiuzhoutong Jiuzhoutong accounts for 4.54% of the retail business, and its main business scope includes the sales of drugs, medical devices and other products and the management of drugstores As of the end of 2018, there are 1287 retail chain drugstores (including franchise stores) in Jiuzhoutong retail.